…er, the impact of antibiotic-induced dysbiosis in patients with multiple myeloma (MM) treated with bispecific antibodies (BsAbs) remains unexplo…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsPopular entities in these results
Choose an entity to see the articles in which it was identified.
Matching articles
29,499 articles · page 325 of 2459…oneliness. The effectiveness of artificial agents used to treat loneliness in this population is contentious in current studies. We aim to…
…on to the fragile arrangements that currently make cross-border cancer care a viable option for many Ukrainian patients. If post-confl…
…borative network and academic conferences. The effectiveness of nirsevimab will be assessed by a test-negative study design, and a two-sta…
…ccess Theses and Dissertations. Eligible studies will report on HIV prevention and/or contraception decision aids and be written in…
…male (82.65%) with an average age of 42 at diagnosis. Secondary APS (63.27%) from systemic lupus (64.29%) was commonly observed.Ini…
…Objectives High disease activity in systemic lupus erythematosus (SLE) significantly impacts life prognosis. Although complement…
…ase (CVD) remains a leading cause of morbidity and mortality in Systemic Lupus Erythematosis (SLE) due to both traditional risk factors and disease-specific…
…AD), potentially mitigating progression to symptomatic disease. Systemic lupus erythematosus (SLE) has an increased risk of accelerated atherosclerotic CAD.…
…rom SLE diagnosisConclusions In this diverse primary care-based SLE cohort, comorbidities and infections were common. GC use was fr…
…le, or the treatments administered compared to patients without LO-SLE.…
…Objectives Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus …